Form 4: Natera Executive Solomon Moshkevich Reports Stock Sale to Cover Tax Obligations

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 2,206 shares of common stock on April 28, 2025, to cover tax obligations related to vesting RSUs.

Summary

• On April 28, 2025, Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 2,206 shares of common stock at a price of $152.1824 per share.
• The sale was executed to satisfy tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs).
• The transaction was made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Moshkevich also made a charitable contribution of 75 shares of common stock.
• Following the reported transactions, Moshkevich beneficially owns 139,205 shares of Natera, Inc.
• Tami Chen, Attorney-in-Fact, signed the report on April 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing relates to a routine stock sale for tax purposes under a pre-arranged plan. It doesn't indicate any fundamental change in the company's prospects or management's view.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The use of a 10b5-1(c) trading plan suggests the sale was pre-planned and not based on insider information.

Stakeholder Impact

• The stock sale may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Natera, NTRA, Solomon Moshkevich, Stock Sale, Form 4, RSUs, Tax Obligations, 10b5-1(c) plan, Beneficial Ownership, Clinical Diagnostics